US 12,448,462 B2
Antibodies against MUC1
Wayne A. Marasco, Wellesley, MA (US); Elizabeth Baez, Ashburn, VA (US); and Matthew Chang, Brookline, MA (US)
Assigned to Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Appl. No. 17/618,363
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US)
PCT Filed Jun. 15, 2020, PCT No. PCT/US2020/037783
§ 371(c)(1), (2) Date Dec. 10, 2021,
PCT Pub. No. WO2020/252472, PCT Pub. Date Dec. 17, 2020.
Claims priority of provisional application 62/861,619, filed on Jun. 14, 2019.
Prior Publication US 2022/0289863 A1, Sep. 15, 2022
Int. Cl. C07K 16/30 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01)
CPC C07K 16/3092 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4257 (2025.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); A61K 2239/13 (2023.05); C07K 2317/21 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01)] 21 Claims
 
1. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to a peptide corresponding to the MUC1-SEA domain (SEQ ID NO: 1) or an epitope thereon, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3), wherein HCDRs 1-3 and LCDRs 1-3 comprise:
a) SEQ ID NO: 2, SEQ ID NO: 96, SEQ ID NO: 104, SEQ ID NO: 7, GKN, and SEQ ID NO: 118;
b) SEQ ID NO: 2, SEQ ID NO: 96, SEQ ID NO: 105, SEQ ID NO: 7, GKN, and SEQ ID NO: 119;
c) SEQ ID NO: 2, SEQ ID NO: 97, SEQ ID NO: 106, SEQ ID NO: 9, GAS, and SEQ ID NO: 120;
d) SEQ ID NO: 2, SEQ ID NO: 96, SEQ ID NO: 107, SEQ ID NO: 7, GKN, and SEQ ID NO: 121;
e) SEQ ID NO: 6, SEQ ID NO: 98, SEQ ID NO: 108, SEQ ID NO: 11, GKN, and SEQ ID NO: 122;
f) SEQ ID NO: 2, SEQ ID NO: 96, SEQ ID NO: 104, SEQ ID NO: 7, GKN, and SEQ ID NO: 123;
g) SEQ ID NO: 2, SEQ ID NO: 96, SEQ ID NO: 109, SEQ ID NO: 7, GKN, and SEQ ID NO: 124;
h) SEQ ID NO: 2, SEQ ID NO: 96, SEQ ID NO: 105, SEQ ID NO: 7, GKN, and SEQ ID NO: 125;
i) SEQ ID NO: 88, SEQ ID NO: 99, SEQ ID NO: 110, SEQ ID NO: 91, GAS, and SEQ ID NO: 126;
j) SEQ ID NO: 6, SEQ ID NO: 98, SEQ ID NO: 111, SEQ ID NO: 11, GKN, and SEQ ID NO: 127;
k) SEQ ID NO: 89, SEQ ID NO: 98, SEQ ID NO: 112, SEQ ID NO: 11, GKN, and SEQ ID NO: 127;
l) SEQ ID NO: 6, SEQ ID NO: 98, SEQ ID NO: 108, SEQ ID NO: 11, GKN, and SEQ ID NO: 127;
m) SEQ ID NO: 2, SEQ ID NO: 100, SEQ ID NO: 113, SEQ ID NO: 92, RNN, and SEQ ID NO: 128;
n) SEQ ID NO: 90, SEQ ID NO: 101, SEQ ID NO: 114, SEQ ID NO: 93, DVS, and SEQ ID NO: 129;
o) SEQ ID NO: 2, SEQ ID NO: 97, SEQ ID NO: 115, SEQ ID NO: 9, GAS, and SEQ ID NO: 130;
p) SEQ ID NO: 2, SEQ ID NO: 102, SEQ ID NO: 116, SEQ ID NO: 94, GAS, and SEQ ID NO: 131; or
q) SEQ ID NO: 6, SEQ ID NO: 103, SEQ ID NO: 117, SEQ ID NO: 95, DVS, and SEQ ID NO: 132; respectively.